Abivax SA

IPO

Abivax | Official Website

Public · Paris, France · Founded 2013 · $1.6B raised

Headquarters
Paris
Employees
51–200
Founded
2013
Business Model
B2B
Website
abivax.com
Total Funding
$1.6B
Last Round
$747.5M Corporate RoundJan 2025
Rounds
5
Type
Public

About

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is an investigational orally administered once-daily small-molecule compound that enhances the expression of miR-124, a naturally occurring microRNA that plays a critical role in regulating the immune response. Obefazimod is currently in Phase 3 clinical trials (ABTECT program) for the treatment of moderately to severely active ulcerative colitis, with additional clinical programs in Crohn's disease and other inflammatory conditions. Abivax is listed on Nasdaq (ABVX) and Euronext Paris.

Summary

Abivax SA is a Biotech company based in Paris, France, founded in 2013. It has raised $1.6B in total across 5 rounds, most recently a $747.5M Corporate Round in Jan 2025. Investors include TCGX and Sofinnova Partners.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundJan 2025
$747.5M

Sign up to see all 7 events

Funding: Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Abivax SA on Indexed.vc
<a href="https://indexed.vc/companies/abivax-sa"><img src="https://indexed.vc/api/badge/company/abivax-sa" alt="Abivax SA on Indexed.vc" width="260" height="76" /></a>